Lantern Pharma (LTRN) announced the establishment of an AI center of excellence and advanced agentic labs in Bengaluru, India. The initiative is designed to industrialize its AI-driven drug discovery capabilities at a global scale. The center will focus on data engineering, refining ML-ready disease models, and integrating with global biopharma customers. Lantern stated the expansion is expected to be cash flow neutral.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN: